KRAS and neoplasm: Additionally, EVs delivering siRNA-KRAS were able to successfully silence KRAS in murine tumor tissues, reducing tumor size; the same technology also enabled the delivery of plasmids to successfully replace/restore genes (Munagala et al., 2021).